Low-Dose Adjuvant Cylinder Brachytherapy for Endometrioid Endometrial Cancer

Publication date: Available online 26 November 2019Source: Practical Radiation OncologyAuthor(s): Gabriela M. Alban, Daniela L. Buscariollo, Teresa Cheng, Jennifer Pretz, Betty Krechmer, Ivan Buzurovic, Lisa Singer, Martin King, Larissa LeeAbstractPurposeOur purpose was to evaluate outcomes and sites of failure for women with early stage endometrial adenocarcinoma treated with adjuvant high-dose-rate (HDR) vaginal brachytherapy (VB) with a low dose scheme.Methods and MaterialsRetrospective review identified 318 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I-II endometrioid endometrial cancer who received adjuvant HDR VB to a dose of 24 Gray (Gy) in 6 fractions from 2005 to 2017. Patients with
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

This report is the first to link components of a unique β-catenin+ endometrioid carcinogenic sequence in the fallopian tube. It further emphasizes the multifocal nature of endometrioid neoplasia in the female genital tract and poses questions regarding the frequency and biologic underpinnings of β-catenin+ proliferations in the oviduct.
Source: International Journal of Gynecological Pathology - Category: Pathology Tags: Pathology of the Upper Tract: Original Articles Source Type: research
We describe the case of a stage IA grade 1 endometrioid endometrial adenocarcinoma diagnosed at the time of missed abortion in a gravida 1 para 0 female with no identifiable risk factors. Fertility-sparing treatment, with combined oral megestrol acetate and levonorgestrel intrauterine system, was used to manage this incidentally-found carcinoma with endometrial sampling every 3 months.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Abstract OBJECTIVES: Enhancer of zeste homolog 2 (EZH2) is a histone methyl transferase that mediates epigenetic silencing of tumor suppressor genes. It is commonly over-expressed in several solid tumors and has been shown to be a prognostic biomarker. We investigated patterns of EZH2 expression in endometrial cancer. METHODS: Evaluation of EZH2 expression was completed on both early and advanced stage endometrioid adenocarcinoma tissues and a subset of matched normal mullerian tissue samples, from participants enrolled in Gynecologic Oncology Group (GOG) protocol 210, using real time reverse transcription po...
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
CONCLUSION: Adjuvant chemotherapy was associated with an overall survival benefit for patients with inadequately-staged, grade 2 stage I ovarian endometrioid adenocarcinoma. A possible benefit for inadequately-staged patients with grade 3 tumors cannot be excluded. PMID: 31839340 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
ConclusionsPositive findings in abdominopelvic washing cytology is rare. The majority of the positive cases were from müllerian origins, with ovary and uterus as the most common sites. Endometrial adenocarcinoma, endometrioid type and ovarian high-grade serous carcinoma were the most common tumor types. Knowing prior history of malignancy, morphologic comparison with concurrent surgical cases, and performing ancillary studies are keys to improve diagnostic accuracy of abdominopelvic washings.
Source: Journal of the American Society of Cytopathology - Category: Cytology Source Type: research
ConclusionEndometrial cancer, specifically type I endometrioid adenocarcinoma and its precursor lesions are strongly associated with unopposed estrogen states such as polycystic ovarian syndrome (PCOS), obesity as well as nulliparity. Patients seeking assisted reproductive technologies make up a subset of these patients and strongly desire to maintain their fertility. Progesterone therapy for select patients may be a safe and effective temporary treatment for endometrial carcinoma and atypical precursor lesions prior to starting IVF-ET. IVF-ET is very effective in treating such patients.
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
ConclusionsPositive findings in abdominopelvic washing cytology is rare. The majority of the positive cases were from müllerian origins with ovary and uterus as the most common sites. Endometrial adenocarcinoma, endometrioid type and ovarian high grade serous carcinoma were the most common tumor types. Knowing prior history of malignancy, morphological comparison with concurrent surgical cases and performing ancillary studies are keys to improve diagnostic accuracy of abdominopelvic washings.
Source: Journal of the American Society of Cytopathology - Category: Cytology Source Type: research
Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinom a;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Gra...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Myoferlin, a protein of the ferlin family, has seven C2 domains and exhibits activity in some cells, including myoblasts and endothelial cells. Recently, myoferlin was identified as a promising target and biomarker in non-small-cell lung cancer, breast cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, colon cancer, melanoma, oropharyngeal squamous cell carcinoma, head and neck squamous cell carcinoma, clear cell renal cell carcinoma and endometrioid carcinoma. This evidence indicated that myoferlin was involved in the proliferation, invasion and migration of tumour cells, the mechanism of which...
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
AbstractHigh-grade endometrial carcinomas are a heterogeneous group of clinically aggressive tumours. They include FIGO grade 3 endometrioid adenocarcinoma, uterine papillary serous carcinoma (UPSC), clear cell carcinoma, undifferentiated carcinoma and carcinosarcomas or malignant mixed Mullerian tumour (MMMT). The aim of this study is to look at clinicopathological features and survival outcomes of high-grade endometrial cancers of the uterus in our centre. A tertiary care centre in India. The study design is retrospective with survival analysis. We did a retrospective analysis of all patients admitted with a diagnosis of...
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Brachytherapy | Cancer | Cancer & Oncology | Carcinoma | Computers | Endometrial Cancer | Endometrioid Carcinoma | OBGYN | Radiation Therapy | Study | Toxicology | Women